{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:00:58Z","timestamp":1793120458389,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00375-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:09:07Z","timestamp":1760360947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1186","volume":"11","author":[{"given":"Germano Dallegrave","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose P.","family":"Lopez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances Caringal","family":"Carandang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Scampoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqqiyah","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Teixeira","family":"Meireles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaris","family":"Balitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenica","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"3","key":"375_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaccao.2023.05.004","volume":"5","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Rankin S, Lang NN. Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2023;5(3):292\u20137.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"375_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10384","key":"375_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","volume":"401","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2023","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277\u201392.","journal-title":"Lancet"},{"issue":"12","key":"375_CR4","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1200\/JCO.23.01428","volume":"42","author":"CE Geyer Jr","year":"2024","unstructured":"Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, et al. Long-term follow-up of the anthracyclines in early breast cancer trials (USOR 06\u2013090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024;42(12):1344\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"375_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"375_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342.","journal-title":"Nat Med"},{"issue":"4","key":"375_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853\u20138.","journal-title":"J Cancer Res Ther"},{"key":"375_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.","journal-title":"BMC Cancer"},{"issue":"16","key":"375_CR9","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314\u201320.","journal-title":"Eur J Cancer"},{"issue":"6","key":"375_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/annonc\/mdf167","volume":"13","author":"LC Kremer","year":"2002","unstructured":"Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13(6):819\u201329.","journal-title":"Ann Oncol"},{"issue":"2","key":"375_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.bjc.6603562","volume":"96","author":"J Bryant","year":"2007","unstructured":"Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer. 2007;96(2):226\u201330.","journal-title":"Br J Cancer"},{"key":"375_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"375_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"5","key":"375_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","volume":"19","author":"G Batist","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444\u201354.","journal-title":"J Clin Oncol"},{"issue":"10","key":"375_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","volume":"15","author":"S Chan","year":"2004","unstructured":"Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15(10):1527\u201334.","journal-title":"Ann Oncol"},{"issue":"3","key":"375_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"375_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94(1):25\u201336.","journal-title":"Cancer"},{"issue":"1","key":"375_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1756-9966-30-39","volume":"30","author":"P Vici","year":"2011","unstructured":"Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, et al. A multicenter prospective phase II randomized trial of epirubicin\/vinorelbine versus pegylated liposomal doxorubicin\/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res. 2011;30(1):39.","journal-title":"J Exp Clin Cancer Res"},{"key":"375_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2018.10.015","volume":"106","author":"A Schneeweiss","year":"2019","unstructured":"Schneeweiss A, Mobus V, Tesch H, Hanusch C, Denkert C, Lubbe K, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. Eur J Cancer. 2019;106:181\u201392.","journal-title":"Eur J Cancer"},{"issue":"4","key":"375_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/cncr.21662","volume":"106","author":"RM Rifkin","year":"2006","unstructured":"Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006;106(4):848\u201358.","journal-title":"Cancer"},{"issue":"7","key":"375_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","volume":"14","author":"MA Dimopoulos","year":"2003","unstructured":"Dimopoulos MA, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003;14(7):1039\u201344.","journal-title":"Ann Oncol"},{"key":"375_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2016.02.004","volume":"58","author":"MA Fridrik","year":"2016","unstructured":"Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT](NHL-14). Eur J Cancer. 2016;58:112\u201321.","journal-title":"Eur J Cancer"},{"issue":"4","key":"375_CR23","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cam4.3730","volume":"10","author":"JM Sancho","year":"2021","unstructured":"Sancho JM, Fernandez-Alvarez R, Gual-Capllonch F, Gonzalez-Garcia E, Grande C, Gutierrez N, et al. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients >\/=60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 2021;10(4):1314\u201326.","journal-title":"Cancer Med"},{"issue":"7","key":"375_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","volume":"37","author":"I Judson","year":"2001","unstructured":"Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870\u20137.","journal-title":"Eur J Cancer"},{"issue":"2","key":"375_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3324\/haematol.2010.027862","volume":"96","author":"M Hunault-Berger","year":"2011","unstructured":"Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica. 2011;96(2):245\u201352.","journal-title":"Haematologica"},{"key":"375_CR26","unstructured":"Program: NCICTE. Responsible Adverse Event (AE) Reporting: Finding Appropriate AE Terms 2018 [Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/CTC.htm.\u00a0 Accessed 4 July 2024."},{"issue":"4","key":"375_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JOP.2016.018770","volume":"13","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2017;13(4):270\u20135.","journal-title":"J Oncol Pract"},{"issue":"5","key":"375_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamacardio.2023.0303","volume":"8","author":"JN Upshaw","year":"2023","unstructured":"Upshaw JN, Nelson J, Rodday AM, Kumar AJ, Klein AK, Konstam MA, et al. Association of preexisting heart failure with outcomes in older patients with diffuse large B-cell lymphoma. JAMA Cardiol. 2023;8(5):453\u201361.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"375_CR29","first-page":"200","volume":"6","author":"JN Upshaw","year":"2024","unstructured":"Upshaw JN, Nelson J, Sweigart B, Rodday AM, Kumar AJ, Konstam MA, et al. Impact of preexisting heart failure on treatment and outcomes in older patients with Hodgkin lymphoma. JACC: CardioOncology. 2024;6(2):200\u201313.","journal-title":"JACC: CardioOncology"},{"issue":"7","key":"375_CR30","first-page":"CD006910","volume":"7","author":"R Newhouse","year":"2023","unstructured":"Newhouse R, Nelissen E, ElShakankery KH, Rogozinska E, Bain E, Veiga S, et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023;7(7):CD006910.","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:09:08Z","timestamp":1760360948000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00375-w","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}